Skip to content

Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab

This report describes the case of a patient with erythrodermic psoriasis who had failed all previous therapies and been hospitalized numerous times over a 12 year period that responded dramatically to treatment with infliximab. Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. Article: Erythrodermic, recalcitrant psoriasis: Clinical resolution with infliximab.

Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab 2Conclusion. Treatment of patients with erythrodermic psoriasis demands a thorough understanding of the treatment options available. This report describes the case of a patient with erythrodermic psoriasis who had failed all previous therapies and been hospitalized numerous times over a 12-year period that responded dramatically to treatment with infliximab. Beneficial effect of infliximab on refractory sarcoidosis. Dan Med J 2012 Dec;59(12):A4535Matilde rum, Ole Hilberg, Susanne Krag, Elisabeth Bendstrup. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatolog Treat 2003 Dec;14(4):222-5F Rongioletti, M Borenstein, Robert Kirsner, Francisco Kerdel.

Erythrodermic psoriasis is a severe forms of psoriasis and it can be life-threatening for the patient. Erythrodermic, recalcitrant psoriasis: Clinical resolution with infliximab. National Psoriasis Foundation benchmark survey on psoriasis and psoriatic arthritis summary of top-line results, 2002. F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.

Treatment Of Erythrodermic Psoriasis: From The Medical Board Of The National Psoriasis Foundation

The potential utility of infliximab as a therapeutic alternative for erythrodermic psoriasis is discussed 3Patients with severely recalcitrant psoriasis represent a subset of patients with comorbidities that exclude both methotrexate and cyclosporine use, but have also had no response to other options for moderate-to-severe psoriasis such as tumor necrosis factor alpha (TNF- )-inhibitors, retinoids, and T-cell inhibiting agents. F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. Erythrodermic CD8+ pseudolymphoma during infliximab treatment in a patient with psoriasis: use of cyclosporine as a rescue therapy. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. Erythrodermic psoriasis is the most severe form of the disease and can be life-threatening. F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. Biologic therapy is recommended only in recalcitrant cases of moderate to severe plaque psoriasis or variants of generalized psoriasis not responsive to conventional antipsoriatic therapies. In a multicentre Japanese study, patients of erythrodermic psoriasis were assessed after infliximab at week 50 and week 66. S. Remission and time of resolution of nail psoriasis during infliximab therapy. F. Erythrodermic, recalcitrant psoriasis: Clinical resolution with Infliximab. The treatments resulted in rapid and complete clearing of psoriatic erythroderma and resolution of symptoms of arthritis in one case and complete clearing of widespread psoriatic plaques and improvement of symptoms of arthritis and inflammatory bowel disease in the other.

Clinical Features Of Erythrodermic Psoriasis